Predictors of latent tuberculosis infection treatment completion in the United States: An inner city experience

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 9, 2010, Pages 1104-1111

  Hirsch Moverman, Yael ^a   Bethel, J ^b   Colson, P W ^a   Franks, J ^a   El Sadr, W ^a  

^a Mailman School of Public Health   (United States)

^b WESTAT   (United States)

Author keywords

Adherence; Latent tuberculosis infection; Treatment completion

Indexed keywords

ISONIAZID;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ATTITUDE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; EDUCATION PROGRAM; FEMALE; HOMELESSNESS; HUMAN; LATENT TUBERCULOSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SOCIAL WORK; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UNITED STATES;

ADULT; ALCOHOL DRINKING; ANTITUBERCULAR AGENTS; EMIGRANTS AND IMMIGRANTS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOMELESS PERSONS; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MARRIAGE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF ADMINISTRATION; SOCIAL ENVIRONMENT; UNITED STATES; URBAN HEALTH;

EID: 77956580710     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bennett D E, Courval J M, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008; 177: 348-355.
2. Geiter L, ed. Ending neglect: the elimination of tuberculosis in the United States. Washington DC, USA: National Academy Press, 2000.
3. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S247. (Pubitemid 30233180)
4. Hirsch-Moverman Y, Daftary A, Franks J, Colson P W. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008; 12: 1235-1254.
5. Horsburgh C R Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 137: 401-409.
6. New York City Department of Health and Mental Hygiene. Tuberculosis in New York City, 2007: information summary. New York, NY, USA: NYC DOHMH, 2008.
7. Chaisson R E, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA 2002; 288: 165-166. (Pubitemid 34755275)
8. Levesque J F, Dongier P, Brassard P, Allard R. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis 2004; 8: 711-717. (Pubitemid 38750206)
9. Lobato M N, Reves R R, Jasmer R M, Grabau J C, Bock N N, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005; 127: 1296-1303. (Pubitemid 46224294)
10. White M C, Tulsky J P, Menendez E, Goldenson J, Kawamura L M. Incidence of TB in inmates with latent TB infection: 5-year follow-up. Am J Prev Med 2005; 29: 295-301.
11. Yun L W, Reves R R, Reichler M R, et al. Outcomes of contact investigation among homeless persons with infectious tuberculosis. Int J Tuberc Lung Dis 2003; 7 (Suppl 3): S405-S411.
12. Bock N, Metzger B, Tapia J, Blumberg H. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999; 159: 295-300.
13. LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-447.
14. Parsyan A E, Saukkonen J, Barry M A, Sharnprapai S, Horsburgh C R Jr. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007; 54: 262-266.
15. Shieh F K, Snyder G, Horsburgh C R, Bernardo J, Murphy C, Saukkonen J J. Predicting non-completion of treatment for l atent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 2006; 174: 717-721.
16. Raffalovich L E, Deane G D, Armstrong D, Tsao H-S. Model selection procedures in social research: Monte-Carlo simulation results. J Applied Stat 2008; 35: 1093-1114.
17. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-723.
18. Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 6: 461-464.
19. Nunnally J. Psychometric theory. New York, NY, USA: McGraw-Hill, 1967.
20. Rieder H L. Epidemiologic basis of tuberculosis control. Paris, France: International Union Against Tuberculosis and Lung Disease, 1999. http://www.theunion.org/component/option,com-guide/Itemid,79/ Accessed June 2010.
21. Mack U, Migliori G B, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
22. Ziakas P D, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49: 1883-1889.